1. 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. (December 2022) Authors: Klinghammer, K.; Saba, N.F.; Castelluci, E.; Colevas, A.D.; Rutkowski, T.; Greil, R.; Thurner, D.; Müller-Richter, U.; Di Giacomo, A.M.; Grewal, J.; Ottensmeier, C.H.H.; Atasoy, A.; Shpyro, S.; Brück, P.; Dias, J.; Ganser, C.; Türeci, Ö.; Sahin, U. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Issue 3 (September 2015) Authors: Zielinski, C.C.; Lang, I.; Inbar, M.; Kahan, Z.; Greil, R.; Beslija, S.; Stemmer, S.M.; Zvirbule, Z.; Steger, G.G.; Melichar, B.; Pienkowski, T.; Sirbu, D.; Petruzelka, L.; Eniu, A.; Nisenbaum, B.; Dank, M.; Anghel, R.; Messinger, D.; Brodowicz, T. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC). (December 2022) Authors: Jerusalem, G.; De Braud, F.G.M.; de Jonge, M.J.A.; Grell, P.; Gonçalves, A.; Tan, T.J.Y.; Greil, R.; Yap, T.A.; Lin, C-C.; Kornbluth, K.A.; Yang, X.; Vong, C.; Choudhury, S.; Mataraza, J.; Lee, L.H.; Otero, J.A.; Garralda, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2098 Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK). (September 2015) Authors: Schreiber, V.; Kitzmueller, M.; Buchner, P.; Weissenboeck, N.; Lichtneckert, M.; Greil, R.; Geiler, H.; Czejka, M.; Dittrich, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2130 Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab + FOLFIRI. (September 2015) Authors: Karthaus, M.; Hofheinz, R.; Mineur, L.; Letocha, H.; Greil, R.; Thaler, J.; Fernebro, E.; Zhang, Y.; Oliner, K.S.; Demonty, G.; Kohne, C.H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Advantages of Taylor‐Couette Flow for Multiphase Operations in the Taylor‐Couette Disc Contactor. Issue 9 (25th August 2022) Authors: Rudelstorfer, G.; Greil, R.; Neubauer, M.; Grafschafter, A.; Siebenhofer, M.; Lux, S. Journal: Chemie Ingenieur Technik Issue: Volume 94:Issue 9(2022) Page Start: 1219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Antihormonal treatment with or without whole breast irradiation in low risk breast cancer patients after breast conserving surgery: 10-year results of the ABCSG 8A trial. (March 2019) Authors: Fastner, G.; Sedlmayer, F.; Widder, J.; Metz, M.; Geinitz, H.; Kapp, K.; Sölkner, L.; Greil, R.; Jakesz, R.; Gnant, M. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Issue 3 (March 2015) Authors: Ramos, F.; Thépot, S.; Pleyer, L.; Maurillo, L.; Itzykson, R.; Bargay, J.; Stauder, R.; Venditti, A.; Seegers, V.; Martínez-Robles, V.; Burgstaller, S.; Récher, C.; Debén, G.; Gaidano, G.; Gardin, C.; Musto, P.; Greil, R.; Sánchez-Guijo, F.; Fenaux, P.; for the European ALMA Investigators, 1 Journal: Leukemia research Issue: Volume 39:Issue 3(2015:Mar.) Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. EBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM‐PET‐POSITIVE ADVANCED‐STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL. (June 2017) Authors: Borchmann, P.; Goergen, H.; Kobe, C.; Eichenauer, D.; Greil, R.; Lohri, A.; Novak, U.; Markova, J.; Beck, H.; Meissner, J.; Zijlstra, J.M.; Ostermann, H.; Feuring‐Buske, M.; Dierlamm, J.; Eich, H.; Baues, C.; Rosenwald, A.; Fuchs, M.; Diehl, V.; Kuhnert, G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2– breast cancer: subgroup analysis of STEPAUT. (March 2017) Authors: Egle, D.; Marth, C.; Steger, G.; Bartsch, R.; Pfeiler, G.; Greil, R.; Helfgott, R.; Öhler, L.; Hennebelle, M.; Gnant, M. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗